CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants of procedural success.

The TAVI-CLOSE study evaluated the efficacy and safety of two femoral access closure strategies after TAVI: closure with a dual suture device (dual Perclose ProGlide) vs a hybrid strategy consisting of a single suture plus a vascular plug (Perclose + Angio-Seal).

This was a prospective, randomized, single-center study conducted in the United States, in which patients were assigned in a 1:1 ratio to one of the two vascular closure strategies. Clinical follow-up extended to 30 days.

The primary endpoint (PE) was a composite of major access-site related bleeding and major vascular complications according to VARC-3 definitions. Secondary endpoints included minor vascular complications and total hospitalization costs.

The incidence of the primary endpoint was 2.1% in the dual suture group vs 7.1% in the suture + plug group. The absolute risk difference was 5% (95% CI −3.8% to 13.8%), exceeding the predefined non-inferiority margin.

Read also: CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon.

No serious events such as death, limb ischemia, embolization, or vascular perforation were reported. Procedural duration, fluoroscopy time, contrast volume, and length of hospital stay (approximately 1.1 days in both groups) were similar between strategies. Likewise, no differences were observed in total hospitalization costs, with a mean cost of approximately $42,000.

TAVI-CLOSE is the first randomized study conducted in the United States comparing vascular closure strategies after TAVI. The study demonstrated a low overall complication rate, with dual suture device closure emerging as the reference strategy.

Presented by Imran Baig at Late Breaking Clinical Trials, CRT 2026, Washington, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHAMPION-AF: Left atrial appendage closure versus anticoagulation in atrial fibrillation

Can left atrial appendage closure challenge anticoagulation as the standard of care in atrial fibrillation? Atrial fibrillation (AF) is the most common sustained arrhythmia and...

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...